Erin Ard
Acute Care · Salisbury, MDNPI 1770966772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 29.9% of the total. Among acute care clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$651
- E.r. Squibb & Sons, L.L.C.$469
- Johnson & Johnson$343
- Novartis$165
- Pfizer$113
- Novo Nordisk$82
- plus $359 from 14 others
What the payments were for
- Food & beverage$2,182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $651 |
| E.r. Squibb & Sons, L.L.C. | 22 | $469 |
| Johnson & Johnson(2 entities) | 22 | $343 |
| Novartis | 8 | $165 |
| Pfizer | 5 | $113 |
| Novo Nordisk | 5 | $82 |
| Lexicon Pharmaceuticals, Inc. | 3 | $58 |
| Kestra Medical Technology Services, Inc. | 2 | $40 |
| Ceribell, Inc. | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| UCB, Inc. | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Amgen | 1 | $19 |
| Gilead | 1 | $19 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,182 in reported general payments places this provider in the 90th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $80 |
| Tamsulosin Hcl | 13 | $78 |
| Oxycodone Hcl | 21 | $38 |
Paid to pharmacies, not to this prescriber.
Other acute care in Salisbury
- Kaci RitcheySalisbury$4K
- Paige GriffithBaltimore$106K
- Amanda ReaPerry Hall$65K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Eleanor DunlapBaltimore$11K
- Tierra AndersonTakoma Park$9K
- Lateaqua AlstonBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.